Katagiri Katsunori, Shiga Kiyoto, Saito Daisuke, Oikawa Shin-Ichi, Ikeda Aya, Tsuchida Kodai, Miyaguchi Jun, Kusaka Takahiro, Kusaka Iori, Ariga Hisanori, Seto Ichiro, Nakasato Tatsuhiko, Koto Masashi
Department of Head and Neck Surgery, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba 028-3695, Japan.
Department of Radiology, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba 028-3695, Japan.
J Clin Med. 2024 Jun 4;13(11):3314. doi: 10.3390/jcm13113314.
: Particle beam therapy (PBT) was approved in April 2018 for head and neck malignancies and has since been introduced as a radical therapy for parotid malignancies. However, its prevalence and effectiveness in relation to surgical treatment have not been investigated. In this study, we evaluated 36 patients with parotid malignancy who underwent surgery (n = 26) or PBT (n = 10) and then analyzed the annual changes in the number of patients, survival rates, and clinical factors affecting prognosis. Of the ten patients who opted for PBT, two and eight patients underwent PBT before and after 2018, respectively. There was a significant difference between these two groups of patients ( = 0.04). Of the ten patients who underwent PBT, five patients were recurrent cases; meanwhile, all twenty-six patients who underwent surgery were receiving initial treatment. Only one patient in each group had local recurrence after the treatment. The use of PBT as a radical therapy for parotid malignancies has been increasing since 2018, and patients with recurrent tumors tended to choose PBT. The outcome of the patients who underwent PBT did not seem to be inferior compared with those of the patients who underwent surgery. The histopathological type was a crucial issue in the outcomes of patients who underwent radical therapy for parotid malignancies.
粒子束治疗（PBT）于2018年4月被批准用于头颈部恶性肿瘤，此后被引入作为腮腺恶性肿瘤的根治性治疗方法。然而，其相对于手术治疗的普及率和有效性尚未得到研究。在本研究中，我们评估了36例接受手术（n = 26）或PBT（n = 10）的腮腺恶性肿瘤患者，然后分析了患者数量的年度变化、生存率以及影响预后的临床因素。在选择PBT的10例患者中，分别有2例和8例患者在2018年之前和之后接受了PBT。这两组患者之间存在显著差异（P = 0.04）。在接受PBT的10例患者中，5例为复发病例；与此同时，所有接受手术的26例患者均接受初始治疗。每组仅1例患者在治疗后出现局部复发。自2018年以来，PBT作为腮腺恶性肿瘤根治性治疗方法的使用一直在增加，复发性肿瘤患者倾向于选择PBT。接受PBT的患者的结局似乎并不比接受手术的患者差。组织病理学类型是腮腺恶性肿瘤根治性治疗患者结局的关键问题。
